4 year highest close., page-2

Now thats what Im talking about !!

Biotechs (refer Bioshares commentary ealier today) are in the zone and POH is at the centre of the sweetspot. We are not the only Bio doing nicely this year but we are the one with a platform tech that has IMHO the most to gain from Ph 3 trials. The forthcoming Oxy Ph 3 trial is both pivotal for the companies first major commerical deal and for future deals based on the TPM platform. If the Oxy patch passes thru these trials successfully, POH has an entire family of patents to commercialise with willing Pharma partners looking to prop up there ailing revenues as their blockbuster drugs come out of patent.